{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T12:45:24Z","timestamp":1782823524884,"version":"3.54.5"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s40256-023-00568-7","type":"journal-article","created":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T10:02:49Z","timestamp":1677924169000},"page":"219-230","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Inclisiran: A Review in Hypercholesterolemia"],"prefix":"10.1007","volume":"23","author":[{"given":"James E.","family":"Frampton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,4]]},"reference":[{"key":"568_CR1","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. Circulation. 2019;139:e1082\u2013143.","journal-title":"Circulation"},{"key":"568_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardio-vascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41:111\u201388.","journal-title":"Eur Heart J"},{"issue":"1","key":"568_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","volume":"5","author":"P Libby","year":"2019","unstructured":"Libby P, Buring JE, Badimon L, et al. Atherosclerosis. Nat Rev Dis Primers. 2019;5(1):56.","journal-title":"Nat Rev Dis Primers"},{"issue":"Suppl","key":"568_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.athx.2019.100002","volume":"39","author":"AL Catapano","year":"2019","unstructured":"Catapano AL, Tokg\u00f6zo\u011flu L, Mello A, et al. Pharmaceutical strategies for reducing LDL-C and risk of cardiovascular disease. Atherosclerosis. 2019;39(Suppl):100002.","journal-title":"Atherosclerosis"},{"issue":"5","key":"568_CR5","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s00392-017-1193-z","volume":"107","author":"KM Fox","year":"2018","unstructured":"Fox KM, Tai MH, Kostev K, et al. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate intensity statins. Clin Res Cardiol. 2018;107(5):380\u20138.","journal-title":"Clin Res Cardiol"},{"key":"568_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2017.11.020","volume":"268","author":"W Marz","year":"2018","unstructured":"Marz W, Dippel FW, Theobald K, et al. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: real-world evidence from Germany. Atherosclerosis. 2018;268:99\u2013107.","journal-title":"Atherosclerosis"},{"key":"568_CR7","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1001\/jamacardio.2017.2289","volume":"2","author":"CP Cannon","year":"2017","unstructured":"Cannon CP, Khan I, Klimchak AC, et al. Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease. JAMA Cardiol. 2017;2:959\u201366.","journal-title":"JAMA Cardiol."},{"key":"568_CR8","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1007\/s12325-020-01285-2","volume":"37","author":"E Bruckert","year":"2020","unstructured":"Bruckert E, Parhofer KG, Gonzalez-Juanatey JR, et al. Proportion of high-risk\/very high-risk patients in Europe with low-density lipoprotein cholesterol at target according to European guidelines: a systematic review. Adv Ther. 2020;37:1724\u201336.","journal-title":"Adv Ther"},{"issue":"16","key":"568_CR9","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s40256-021-00477-7","volume":"21","author":"J Hardy","year":"2021","unstructured":"Hardy J, Niman S, Pereira E, et al. A critical review of the efficacy and safety of inclisiran. Am J Cardiovasc Drugs. 2021;21(16):629\u201342.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"4","key":"568_CR10","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.jacl.2016.04.010","volume":"10","author":"H Halava","year":"2016","unstructured":"Halava H, Huupponen R, Pentti J, et al. Predictors of first-year statin medication discontinuation: a cohort study. J Clin Lipidol. 2016;10(4):987\u201395.","journal-title":"J Clin Lipidol"},{"key":"568_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.789931","volume":"8","author":"C Bardolia","year":"2021","unstructured":"Bardolia C, Amin NS, Turgeon J. Emerging non-statin treatment options for lowering low-density lipoprotein cholesterol. Front Cardiovasc Med. 2021;8:789931.","journal-title":"Front Cardiovasc Med."},{"key":"568_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/10742484221100107","volume":"27","author":"C Coppinger","year":"2022","unstructured":"Coppinger C, Movahed MR, Azemawah V, et al. A comprehensive review of PCSK9 inhibitors. J Cardiovasc Pharmacol Ther. 2022;27:1\u201314.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"568_CR13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11883-020-00847-7","volume":"22","author":"AL Catapano","year":"2020","unstructured":"Catapano AL, Pirillo A, Norata GD. New pharmacological approaches to target PCSK9. Curr Atheroscler Rep. 2020;22:24.","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"568_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40259-019-00399-6","volume":"34","author":"CA German","year":"2020","unstructured":"German CA, Shapiro MD. Small interfering RNA therapeutic inclisiran: a new approach to targeting PCSK9. BioDrugs. 2020;34(1):1\u20139.","journal-title":"BioDrugs"},{"issue":"8","key":"568_CR15","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.ajpath.2021.04.016","volume":"191","author":"C Macchi","year":"2021","unstructured":"Macchi C, Ferri N, Sirtori CR, et al. Proprotein convertase subtilisin\/kexin type 9: a view beyond the canonical cholesterol-lowering impact. Am J Pathol. 2021;191(8):1385\u201397.","journal-title":"Am J Pathol"},{"key":"568_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jacl.2019.11.001","volume":"14","author":"KM Dyrbus","year":"2020","unstructured":"Dyrbus KM, Gasior MM, Penson PM, et al. Inclisiran: new hope in the management of lipid disorders? J Clin Lipidol. 2020;14:16\u201327.","journal-title":"J Clin Lipidol"},{"issue":"3","key":"568_CR17","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","volume":"81","author":"YN Lamb","year":"2021","unstructured":"Lamb YN. Inclisiran: first approval. Drugs. 2021;81(3):389\u201395.","journal-title":"Drugs"},{"key":"568_CR18","unstructured":"Novartis Europharm Limited. Leqvio 284 mg solution for injection in pre-filled syringe: EU prescribing information. 2021. https:\/\/www.ema.europa.eu. Accessed 24 Jan 2023."},{"key":"568_CR19","unstructured":"Novartis Pharmaceuticals Corporation. LEQVIO (inclisiran) injection, for subcutaneous use: US prescribing information. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214012lbl.pdf. Accessed 24 Jan 2023."},{"key":"568_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104413","volume":"150","author":"C Macchi","year":"2019","unstructured":"Macchi C, Sirtori CR, Corsini A, et al. A new dawn for managing dyslipidemias: the era of RNA-based therapies. Pharmacol Res. 2019;150:104413.","journal-title":"Pharmacol Res"},{"issue":"15","key":"568_CR21","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","volume":"376","author":"KK Ray","year":"2017","unstructured":"Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430\u201340.","journal-title":"N Engl J Med"},{"issue":"11","key":"568_CR22","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1001\/jamacardio.2019.3502","volume":"4","author":"KK Ray","year":"2019","unstructured":"Ray KK, Stoekenbroek RM, Kallend D, et al. Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial. JAMA Cardiol. 2019;4(11):1067\u201375.","journal-title":"JAMA Cardiol."},{"key":"568_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00353-9","author":"KK Ray","year":"2023","unstructured":"Ray KK, Troquay RPT, Visseren FLJ, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 2023. https:\/\/doi.org\/10.1016\/S2213-8587(22)00353-9.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"568_CR24","unstructured":"European Medicines Agency. Leqvio (inclisiran) assessment report. 2020. https:\/\/www.ema.europa.eu. Accessed 24 Jan 2023."},{"issue":"1","key":"568_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.mayocp.2019.08.021","volume":"95","author":"RS Wright","year":"2020","unstructured":"Wright RS, Collins MG, Stoekenbroek RM, et al. Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies. Mayo Clin Proc. 2020;95(1):77\u201389.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"568_CR26","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jacl.2022.01.001","volume":"16","author":"D Kallend","year":"2022","unstructured":"Kallend D, Stoekenbroek R, He Y, et al. Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment. J Clin Lipidol. 2022;16(2):208\u201319.","journal-title":"J Clin Lipidol"},{"issue":"16","key":"568_CR27","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507\u201319.","journal-title":"N Engl J Med"},{"issue":"16","key":"568_CR28","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","volume":"382","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520\u201330.","journal-title":"N Engl J Med"},{"key":"568_CR29","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.atherosclerosis.2020.10.036","volume":"315","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Kallend D, Ray KK, et al. Inclisiran reduces LDL-cholesterol independent of genotype in subjects with heterozygous familial hypercholesterolaemia [abstract no. 018 \/ #1707]. Atherosclerosis. 2020;315:e7\u20138.","journal-title":"Atherosclerosis"},{"issue":"9","key":"568_CR30","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.jacc.2020.12.058","volume":"77","author":"RS Wright","year":"2021","unstructured":"Wright RS, Ray KK, Raal FJ, et al. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J Am Coll Cardiol. 2021;77(9):1182\u201393.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"568_CR31","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/eurheartj\/ehac594","volume":"44","author":"KK Ray","year":"2022","unstructured":"Ray KK, Raal FJ, Kallend DG, et al. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. 2022;44(2):129\u201338.","journal-title":"Eur Heart J"},{"issue":"1","key":"568_CR32","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/cvr\/cvaa077","volume":"117","author":"U Landmesser","year":"2021","unstructured":"Landmesser U, Haghikia A, Leiter LA, et al. Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin\/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1. Cardiovasc Res. 2021;117(1):284\u201391.","journal-title":"Cardiovasc Res"},{"key":"568_CR33","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1093\/eurheartj\/ehy723","volume":"39","author":"PM Ridker","year":"2018","unstructured":"Ridker PM, Koenig W, Kastelein JJ, et al. Has the time finally come to measure hsCRP universally in primary and secondary cardiovascular prevention? Eur Heart J. 2018;39:4109\u201311.","journal-title":"Eur Heart J"},{"key":"568_CR34","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1016\/j.atherosclerosis.2021.06.106","volume":"331","author":"U Landmesser","year":"2021","unstructured":"Landmesser U, Conde LG, Wright RS, et al. Effect of inclisiran on haematological and immunological biomarkers: a pooled analysis of ORION-9, -10 and -11 trial data [abstract no. S025 \/ #1062]. Atherosclerosis. 2021;331:e37.","journal-title":"Atherosclerosis"},{"issue":"34","key":"568_CR35","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227\u201337.","journal-title":"Eur Heart J"},{"key":"568_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac615","author":"KK Ray","year":"2022","unstructured":"Ray KK, Kallend D, Leiter LA, et al. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J. 2022. https:\/\/doi.org\/10.1093\/eurheartj\/ehac615.","journal-title":"Eur Heart J"},{"issue":"5","key":"568_CR37","doi-asserted-by":"publisher","first-page":"769","DOI":"10.2217\/fca-2020-0150","volume":"17","author":"J Brandts","year":"2021","unstructured":"Brandts J, Ray KK. Clinical implications and outcomes of the ORION phase III trials. Future Cardiol. 2021;17(5):769\u201377.","journal-title":"Future Cardiol"},{"key":"568_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biopha.2021.112227","volume":"143","author":"P Scicchitano","year":"2021","unstructured":"Scicchitano P, Milo M, Mallamaci R, et al. Inclisiran in lipid management: a literature overview and future perspectives. Biomed Pharmacother. 2021;143:1\u201315.","journal-title":"Biomed Pharmacother"},{"issue":"9 Suppl. A","key":"568_CR39","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0735-1097(22)02542-6","volume":"79","author":"C Campbell","year":"2022","unstructured":"Campbell C, Desai NR, Electricwala B, et al. The comparative efficacy of inclisiran, PCSK9 inhibiting monoclonal antibodies, and ezetimibe for the treatment of high cholesterol in adults with or at risk of ASCVD: a systematic literature review and network meta-analysis. J Am Coll Cardiol. 2022;79(9 Suppl. A):1551.","journal-title":"J Am Coll Cardiol."},{"issue":"5","key":"568_CR40","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/03007995.2022.2049164","volume":"38","author":"H Burnett","year":"2022","unstructured":"Burnett H, Fahrbach K, Cichewicz A, et al. Comparative efficacy of non-statin lipid-lowering therapies in patients with hypercholesterolemia at increased cardiovascular risk: a network meta-analysis. Curr Med Res Opin. 2022;38(5):777\u201384.","journal-title":"Curr Med Res Opin"},{"key":"568_CR41","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.atherosclerosis.2021.03.042","volume":"325","author":"J Brandts","year":"2021","unstructured":"Brandts J, Dharmayat KI, Vallejo-Vaz AJ, et al. A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia. Atherosclerosis. 2021;325:46\u201356.","journal-title":"Atherosclerosis"},{"key":"568_CR42","doi-asserted-by":"publisher","first-page":"8129513","DOI":"10.1155\/2022\/8129513","volume":"2022","author":"I Mer\u0107ep","year":"2022","unstructured":"Mer\u0107ep I, Fri\u0161\u010di\u0107 N, Striki\u0107 D, et al. Advantages and disadvantages of inclisiran: a small interfering ribonucleic acid molecule targeting PCSK9\u2014a narrative review. Cardiovasc Ther. 2022;2022:8129513.","journal-title":"Cardiovasc Ther"},{"issue":"11","key":"568_CR43","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1093\/cvr\/cvaa212","volume":"116","author":"AJ Cupido","year":"2020","unstructured":"Cupido AJ, Kastelein JJP. Inclisiran for the treatment of hypercholesterolaemia: implications and unanswered questions from the ORION trials. Cardiovasc Res. 2020;116(11):e136\u20139.","journal-title":"Cardiovasc Res"},{"key":"568_CR44","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s10741-019-09874-2","volume":"25","author":"S Azari","year":"2020","unstructured":"Azari S, Rezapour A, Omidi N, et al. Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review. Heart Fail Rev. 2020;25:1077\u201388.","journal-title":"Heart Fail Rev"},{"key":"568_CR45","unstructured":"Lin G, Kazi D, Jih J, et al. Inclisiran and bempedoic acid for patients with heterozygous familial hypercholesterolemia and for secondary prevention of ASCVD: effectiveness and value; evidence report: Institute for Clinical and Economic Review. Mar 2, 2021. http:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_High-Cholesterol_Final-Evidence-Report_030221.pdf. Accessed 24 Jan 2023."},{"issue":"9 Suppl. A","key":"568_CR46","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/S0735-1097(22)02550-5","volume":"79","author":"C Campbell","year":"2022","unstructured":"Campbell C, Desai NR, Electricwala B, et al. Cost-effectiveness of inclisiran in atherosclerotic cardiovascular patients with elevated low-density lipoprotein cholesterol despite statin use: a threshold analysis [abstract]. J Am Coll Cardiol. 2022;79(9 Suppl. A):1559.","journal-title":"J Am Coll Cardiol."},{"key":"568_CR47","unstructured":"National Institute for Health and Clinical Care Excellence. Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia. Technology appraisal guidance [TA733]. 2021. https:\/\/www.nice.org.uk\/. Accessed 24 Jan 2023."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-023-00568-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-023-00568-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-023-00568-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T15:37:08Z","timestamp":1678462628000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-023-00568-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["568"],"URL":"https:\/\/doi.org\/10.1007\/s40256-023-00568-7","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"11 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"James E. Frampton is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}